Actively Recruiting
Phase 1 Study Evaluating ASP1002 Alone or With Chemotherapy and Immunotherapy in Adults with Advanced or Metastatic Solid Tumors
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-07-23
798
Participants Needed
15
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ASP1002 in adults with advanced or metastatic solid tumors that cannot be removed by surgery or have spread to other parts of the body. ASP1002 targets the Claudin 4 protein found on various tumors and is designed to activate the immune system to attack cancer cells. This early phase 1 study focuses primarily on assessing the safety, tolerability, and appropriate dosing of ASP1002 alone and combined with standard chemotherapies and immunotherapies in people previously treated or who have declined standard therapies. Participants will receive ASP1002 by intravenous infusion alone or together with standard chemotherapy drugs such as mFOLFOX6, FOLFIRI, TAS-102, pemetrexed, carboplatin, or docetaxel, and immunotherapies including bevacizumab, pembrolizumab, or ramucirumab. Treatment is given every 2 to 4 weeks in cycles lasting 21 or 28 days. The study has two parts Part 1 tests increasing doses of ASP1002 alone and with other treatments to find suitable doses, while Part 2 uses doses and combinations identified in Part 1 for further evaluation. During the study, participants will attend clinic visits for health checks, safety monitoring, and to report any medical issues. Every two months, scans such as CT or MRI will assess tumor response. Tumor samples will be collected before and during treatment, with optional samples after treatment ends. Follow-up visits will continue for up to one year after the last dose or until starting a new study treatment. Researchers will measure safety outcomes including side effects and laboratory results, as well as treatment effects on tumors and immune response.
CONDITIONS
Brief Title
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Research Team
A
Astellas Pharma Global Development, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here